KIT and angiosarcoma: Another multikinase inhibitor, sorafenib, targets the kinases Raf, PDGF, VEGFR2, VEGFR3, and c-Kit, was only proven to be effective against angiosarcoma in a phase 2 trial, with 5/37 patients exhibiting at least a partial response.